Flavoured water consumption alters pharmacokinetic parameters and increases exposure of erlotinib and gefitinib in a preclinical study using Wistar rats
Background Erlotinib (ERL) and Gefitinib (GEF) are considered first line therapy for the management of non-small cell lung carcinoma (NSCLC). Like other tyrosine kinase inhibitors (TKIs), ERL and GEF are mainly metabolized by the cytochrome P450 (CYP450) CYP3A4 isoform and are substrates for transpo...
Main Authors: | Aliyah Almomen, Hadir M. Maher, Nourah Z. Alzoman, Shereen M. Shehata, Amal Alsubaie |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2020-09-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/9881.pdf |
Similar Items
-
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
by: Ye Jiang, et al.
Published: (2018-11-01) -
The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of
Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01) -
Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01) -
Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan
by: Thu-Lan T. Luong, et al.
Published: (2021-01-01) -
A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
by: Preenumol Thomas, et al.
Published: (2019-01-01)